Studies involving multiple aspects of plaque psoriasis evolution, persistence, and progression have produced clues and ...

Substantial savings opportunities exist by using lower-cost biologics for patients with plaque psoriasis, according to one ...

About 58% of patients with psoriasis achieved super responder status with guselkumab, characterised by complete skin ...

Sanofi’s development of an oral spin on Humira’s mechanism has hit a setback. | Sanofi’s development of an oral spin on ...

Biologics targeting interleukin (IL)-12, IL-23, and IL-17 may have valuable safety benefits among older adults with psoriatic disease, as a lower rate of serious infection was observed among these ...

Clinical efficacy was evaluated using the Psoriasis Area and Severity Index (PASI), along with metabolic indicators such as ...

Art Garfunkel discusses his experience living with psoriasis as part of Sun Pharma’s I LUV YA for The Long Haul campaign.

GLP-1s exploded seemingly out of nowhere, straining pharmacy plan bottom lines. Psoriasis treatments don't have to follow the ...

An expert discusses how comparative studies of FDA-approved psoriasis biologics are crucial for treatment optimization. This study compared tildrakizumab with ustekinumab, analyzing discontinuation, ...

The following is a summary of “Treatment of plaque psoriasis with guselkumab reduces systemic inflammatory burden as measured by neutrophil/lymphocyte ratio, platelet/lymphocyte ratio and ...

Patanjali Ayurved has achieved another milestone that could lead to a major breakthrough in the treatment of 'psoriasis', a ...